Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

66.41 +0.25 (+0.38%)
Streaming Delayed Price Updated: 1:15 PM EDT, Apr 19, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,364,436
Open 66.25
Bid (Size) 66.41 (1)
Ask (Size) 66.42 (7)
Prev. Close 66.16
Today's Range 66.16 - 66.72
52wk Range 65.90 - 87.86
Shares Outstanding 1,253,809,440
Dividend Yield 4.52%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
What the Options Market Tells Us About Gilead Sciences
Via Benzinga

Performance

YTD
-20.22%
-20.22%
1 Month
-9.54%
-9.54%
3 Month
-23.14%
-23.14%
6 Month
-15.34%
-15.34%
1 Year
-21.05%
-21.05%

More News

Read More
If You Invested $100 In This Stock 20 Years Ago, You Would Have $900 Today
Via Benzinga
Why the dividend investor may take a look at NASDAQ:GILD.
Via Chartmill
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Via The Motley Fool
Should You Buy the 3 Highest-Paying Dividend Stocks in the Nasdaq?
Via The Motley Fool
If You Invested $100 In This Stock 20 Years Ago, You Would Have $1,000 Today
Via Benzinga
Biotech Innovations Paving the Way in Breast Cancer Fight
Via FinancialNewsMedia
Topics Death
Exposures Death Product Safety
Top 3 Health Care Stocks Which Could Rescue Your Portfolio This Quarter
Via Benzinga
3 Stocks at 52-Week Lows Poised for a Powerful Rebound
Via InvestorPlace
10 Health Care Stocks With Whale Alerts In Today's Session
Via Benzinga
Gilead Sciences to Release First Quarter 2024 Financial Results on Thursday, April 25, 2024
From Gilead Sciences, Inc.
Via Business Wire
Starbucks, Gilead And Ambev Are At 52-Week Lows: Should You Buy The Dip?
Via Benzinga
3 No-Brainer Dividend Stocks to Buy in April
Via The Motley Fool
Got $5,000? These 3 High-Yielding Dividend Stocks Are Trading Near Their 52-Week Lows
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Biotech Sector Nears Breakout: Will it Outperform in Q2?
Via MarketBeat
Topics ETFs
5 Healthcare Stocks to Buy for 2024
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Galapagos Downgraded, Pharma Firm Faces Uphill Battle With Slow Pipeline Progress: Analyst
Via Benzinga
10 Big-Name Stocks Near 52 Week Lows: Are They A Buy?
Via Talk Markets
Cancer Focused Micro-Cap Xilio Therapeutics Stock Doubles In One Session - Here's Why
Via Benzinga
Why Is Xilio Therapeutics (XLO) Stock up 168% Today?
Via InvestorPlace
FDA Expands Indication for Gilead's Vemlidy (Tenofovir Alafenamide) to Treat Chronic HBV Infection in Pediatric Patients as Young as Six
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
From Xilio Therapeutics, Inc.; Gilead Sciences, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.